Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Brain scan study aims to spot Alzheimer's years early

NCT ID NCT05138263

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 640 adults with normal cognition, mild cognitive impairment, or Alzheimer's disease to track brain changes over time. Researchers use advanced brain scans and genetic tests to understand how Alzheimer's develops. The goal is to find better ways to diagnose and predict the disease early.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help doctors detect Alzheimer's earlier and predict who might develop it, leading to better planning and care.
What could go wrong
This is an observational study, not a treatment trial. It may not directly lead to new therapies, and results may take years to apply in practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 640 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2022

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Young and elderly normal controls: community-based population AD and MCI: clinic or community-based population

Ages

20 to 90 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Participants will be classified as either Alzheimer's disease(AD) group, mild cognitive impairment(MCI) group, elderly normal controls or young normal controls. Specific inclusion criteria for each group is described below. Inclusion Criteria: \[Inclusion criteria: AD\] * Age : 55 - 90 * Clinical Dementia Rating (CDR)=0.5 or 1 * Diagnostic and Statistical Manual-IV(DSM-IV) criteria for dementia * National Institute of Aging and the Alzheimer's Association (NIA-AA) Probable AD dementia * Study partner or caregiver to accompany patient to all scheduled visits * Written informed consent \[Inclusion criteria: MCI (amnestic)\] * Age : 55 - 90 * Clinical Dementia Rating (CDR)=0.5 * Concern regarding a change in cognition (obtained from the subject, from an informant who knows the subject, or from a skilled clinician observing the subject) * Lower performance in any cognitive domain that is greater than would be expected for the subject's age and educational background * Preservation of independence in functional abilities * Study partner or caregiver to accompany subject to all scheduled visits * Written informed consent \[Inclusion criteria: Elderly normal controls\] * Age : 55 - 90 * Clinical Dementia Rating (CDR)=0 * Those with contactable Informant * Written informed consent \[Inclusion criteria: Young normal controls\] * Age : 20 - 54 * Clinical Dementia Rating (CDR)=0 * Written informed consent Exclusion Criteria: \[Exclusion criteria: general\] * Past history or presence of major psychiatric illness (e.g. schizophrenia, bipolar disorder, alcohol/substance abuse or dependence, delirium) * Significant neurologic or medical condition that can influence the mental state * Contraindications for MRI scan (e.g. pacemaker, claustrophobia) * Illiteracy * Significant visual or hearing difficulty * Taking investigational drug * In pregnancy or breast-feeding

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Alzheimer disease Cognitive Dysfunction disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • SMG-SNU Boramae Medical Center

    Seoul, Seoul, South Korea

  • Seoul National University Hospital

    Seoul, 03080, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.